新型棘白菌素类抗真菌药阿尼芬净
时间:2025-04-20
时间:2025-04-20
垦!i!!!!!!!翌!!!!!!兰旦!!g!!塑i:∑!!:!!堕!:!!
lipid
中国新药杂志2005年第14卷第1l期
mildronate[JJ.hjtrdiologiia,1991,31(1):17一19.
Rupp
H,Zarain—HerzbergA,Maisch
formetabolic
B.The
use
levelsin
ratslJj.BiofPharmBulf,2000,23(6):770—773.
K,Kifimoto
T,et
[6]
HayashiY,Tajimaa1.Cardioprotectiveeffectsof
ofpartial
fattyacid
MET.88.adysfunction
gamma.butyrobetaine
hydroxylaseinhibitor.oncardiac
isolated
rat
oxidationinhibitors
therapyofangina
peetorisandheart
inducedbyisehemia/reperfusionin
hearts[J].
[12]
new
failurelJJ.胁K,2002,27(7):621—636.
SakharchukⅡ,SisetskiiAP,Artiukh
activityin
patients
VP,et
Pharmacology,2000,61(4):238—243.
af.Erythroeytefunctional
possible
means
for
its
[72
Klin
E.ne
toxicity
researchofMET.88(Mildronate),awithheartfailureandthe
eardioprotective
agentlJJ.Farmakoter,1991,19(3):67—71.
Iia,Anisimovpropertiesin
VN,et
correction[Jj.TerArkh,1992,64(9):88—90.
of
[8]
Belitskii
GA,Kalvinysh
a1.Absenee
[13]
NedoshivinAO,treatment
Kutuzova
of
AE.Perepech
NB.Mildronatein
mutagenic
andcarcinogenicmildronate[J].VoprOnkol,
[14]
combinedchroniccardiac
insufficiency
lJJ.日inMed
19919,45(3):279—282.(Mosk),1999,77(3):41—43.
and
[9]
YoshisueK,YamamotoY,YosbidaK,et“.Pharmacokinetiesbiological
fate
of
Nedosbivinmildronate
AO,Petrova
on
NN,KutuzovaAE,甜4.
chronic
heart
EⅡjct0f
3-(2,2,
novel
2-trimethylhydr船inium)propionate
cardioprotective
agent,in
lifequalityofpatientswith
failure[J].
dihydrate(MET-88),a
Drug
rats[J].死rArkh,1999,71(8):10—12.
Metab
Dispos,2000,28(6):687—694.
EB,Zhemerikina
coronary
EV,et
[10]
Savehukclinieal
VI,Novikova
a1.Experimentaland
administration
of
(接受日期:2005—07—18)
studiesofcirculationafter
新型棘白菌素类抗真菌药阿尼芬净
曹国颖,傅得兴
(卫生部北京医院药学部,北京100730)
[摘要】
阿尼芬净(anidulafungin,VER.002;LY303366),是第三代棘白菌素类的半合成抗真菌药,是两性霉素B
的衍生物,由美国Vicuron制药公司研制,同其他棘白菌素类抗真菌药比较,分布容积更大,抗菌谱更广,目前在美国处于Ⅲ期临床试验阶段。介绍阿尼芬净的作用机制、药效学、药动学和临床评价。
[关键词]
阿尼芬净;作用机制;药动学;临床评价
上一篇:模拟电子技术实验报告模版
下一篇:二元一次方程组应用题专项练习教案